This 3-year follow-up compared insomnia treatment to depression treatment for patients with both diagnoses. Forty-three participants were randomized to either treatment, in the form of Internet-delivered therapist-guided cognitive behavior therapy (CBT), and 37 (86%) participants provided primary outcome data at the 3-year follow-up. After 3 years, reductions on depression severity were similar in both groups (between-group effect size, d = 0.33, p = .45), while the insomnia treatment had superior effects on insomnia severity (d = 0.66, p < .05). Overall, insomnia treatment was thus more beneficial than depression treatment. The implication for practitioners, supported by previous research, is that patients with co-occurring depression and insomnia should be offered CBT for insomnia, in addition to medication or psychological treatment for depression.
INTRODUCTION
Major depression is well known as a highly prevalent, serious, and costly disorder for individuals and society. Sleep problems in the form of insomnia disorder are even more common but have historically been seen as symptoms secondary to other disorders. However, insomnia leads to great suffering and large societal costs. 1 A majority of depressed individuals have co-occurring insomnia, but the view that sleep problems are secondary to depression is challenged by accumulating evidence: insomnia is a risk factor for depression, 2,3 depression treatment is not a sufficient remedy for insomnia, 4 ,5 insomnia hinders recovery from depression, 6, 7 and residual insomnia increases the risk for depression relapse. 8, 9 These and other findings have resulted in updates of diagnosis manuals, 10, 11 to reflect that insomnia disorder can and should be diagnosed as a comorbid, rather than secondary disorder when co-occurring with other disorders. Still, treatment practices have not yet shifted accordingly, and comorbid insomnia is thus often not adequately treated. National treatment guidelines for psychiatric disorders (eg, NICE, APA) generally focus on depression, and guidelines for insomnia are often missing entirely.
Cognitive behavior therapy (CBT) for insomnia (CBT-i) has superior long-term effects compared to sleep medication. 12 It is also what most patients prefer but rarely get. 13, 14 A way of increasing access to CBT-i is to provide it via the Internet (ICBT-i), which in many studies has been proven effective, 15, 16 as has CBT for depression (ICBT-d). 17 There are, however, very few randomized controlled follow-ups of more than 6-12 months for depression and insomnia treatments.
In order to challenge the treatment paradigm for co-occurring insomnia and depression, we compared ICBT-i to ICBT-d for patients with both diagnoses. Our previously published results from this randomized controlled trial (RCT), with a 12-month follow-up, showed that ICBT-i was overall more beneficial than ICBT-d: its effects on insomnia were larger, while the effects on depression were similar in both groups. Participants in ICBT-i also reduced their sleep medication use more and had lower self-rated need for further treatment. 18 This brief report presents a 36-month follow-up of our previous RCT, to explore whether the superiority of the insomnia treatment is maintained.
METHOD
This was a 36-month follow-up (FU36) of an RCT conducted at the Internet Psychiatry Clinic in Stockholm, Sweden. The study is described in more detail in the original report. 18 Participants were 43 adults (53% women, mean age 47 years, 63% used sleep medication and 30% antidepressants) diagnosed with major depression and insomnia by psychiatrists using the M.I.N.I. interview. 19 Other comorbidities were allowed, except sleep apnea, narcolepsy, and bipolar disorder. Primary outcome measures were the Self-Rated Montgomery Åsberg Depression Rating Scale (MADRS-S) [20] [21] [22] and the Insomnia Severity Index (ISI). [23] [24] [25] [26] [27] Secondary measures at the 36-month follow-up were remission rates and use of sleep and depression medication. See Figure 1 for a study flow chart.
Patients were randomized to 9 weeks of therapist-guided Internet-delivered CBT, either for insomnia (ICBT-i) or for
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depression (ICBT-d).
ICBT-d has been tested in an RCT, using a recommended treatment length of 8 weeks and ending up with an average treatment time of 10 weeks. 28 It has also been used in regular care at the Internet Psychiatry Clinic since 2007, with a treatment time of 12 weeks to allow for 2 weeks' absence. Data from the first 1203 patients have been reported in an effectiveness study. 29 The original treatment included a module on sleep, which was removed for the purpose of this trial and allowed for a 9-week treatment window, with one module per week. The insomnia treatment, ICBT-i, has been tested in two RCTs, 30, 31 including one 3-year follow-up, 32 using a treatment time of 8 weeks. More detailed information about the treatments can be found in the original article. The follow-up data presented here were collected using self-rated online questionnaires and blinded telephone interviews, used for diagnosing and to impute primary data for those with missing online data, according to the method described by Hedman et al. 33 Statistics used were hierarchical linear mixed effect modeling, to handle missing data and ensure an intent-to-treat analysis. 34, 35 The data were best modeled by using two periods; time-piece 1 from pre to post, including eight weekly measures, and time-piece 2 from post to FU36, including follow-ups after 6 and 12 months (FU6 and FU12). The final model had a random intercept, a time × group interaction for time-piece 1, and no interaction for timepiece 2, that is, the groups had parallel slopes during the follow-up period. Since MADRS-S has an item measuring sleep, a sensitivity analysis was done for MADRS-S without the sleep item. Chi-square or Fisher exact test was used for dichotomous data. Cohen's d for effect size was based on observed data. The trial was registered at clinicaltrials.gov (NCT01256099) and approved by the Regional Ethical Review Board in Stockholm (2009/1810-31/3).
RESULTS
The follow-up response rate at FU36 was high, (86%, see Figure 1 ). Table 1 Blinded telephone assessments at FU36 diagnosed major depression in six, that is, 35%, of the interviewed participants in ICBT-i, and eight, that is, 57%, of the interviewed participants in ICBT-d, and insomnia in six from each group (33% and 43%, respectively). At FU36, three participants in ICBT-i used sleep medication daily and four used it irregularly, while six in ICBT-d used sleep medication daily. Eight participants in ICBT-i versus five in ICBT-d used antidepressant medication. None of these differences were statistically significant.
DISCUSSION
After 3 years, the improvements in both symptom areas were maintained. The insomnia treatment was superior to the depression treatment with regard to insomnia symptoms, while there was no significant difference between treatment groups in symptoms of depression. Fifty-six and 62% of the interviewed participants no longer had a diagnosis of depression and insomnia, respectively. Contrary to the findings up to the 12-month follow-up, 18 there were no significant differences between groups regarding the number of remitters or sleep medication users, the latter being reduced by 50% compared to baseline in both groups. Previously, only one study of CBT-i has had an equally long follow-up period, also reporting maintained improvements. 32 Another recent study, comparing antidepressants plus CBT-i to antidepressants plus a control treatment, had similar results: effects on depression were similar in both groups and effects on insomnia were larger in the CBT-i group. They also found that improvements in insomnia mediated depression outcomes. 36 A possible explanation to our findings, is that insomnia needs to be treated with specific methods that have specific effects, 37 ,38 while many different types of depression treatment have been found effective, as long as they were structured and delivered with quality. 39 In fact, several previous studies of CBT-i have reported reduced levels of co-occurring depressive symptoms after treatment. [40] [41] [42] In a qualitative study of the sample in our study, we found that participants in ICBT-i were more positive about the treatment than those in ICBT-d, and that higher symptom levels and additional comorbidities were more hindering in the work with ICBT-d. 43 Even though symptom reductions were large for ICBT-i and moderate to large for ICBT-d, the symptom levels after 30 years were less than satisfactory. At baseline, the participants had unusually high symptom levels, compared to other studies, and 51% reported sleeping less than 6 hours on average. The aforementioned qualitative study indicated that this is likely to have hindered their work with the treatments, especially in ICBT-d, and another recent study found that insomniacs with short objective sleep duration were less responsive to CBT-i. 44 Our results indicate that while ICBT-i was superior, it is likely not a sufficient treatment for a majority of these patients.
A limitation of this study is the small sample size and thereby low statistical power. Even though we found significant differences for insomnia severity, the nonsignificant results, particularly on depression severity, may be the result of low power. The small sample size also makes the issue with missing data at the 3-year follow-up extra important, even though the relative number of missing data is rather small for a long-term follow-up. We handle attrition by using the recommended way to control for missing data, hierarchical linear mixed effect modeling, 34, 35 to ensure an intent-to-treat-analysis that is state-of-the-art. Another limitation is the depression treatment length. Though supported by the previous evidence for the same treatment program, 28, 29 it was shorter than many face-to-face treatments for depression, and outcomes might have been different if we had used another mode of delivery or treatment length. Also, this study used guided Internet treatments, which may impact the characteristics of the participants and their involvement in the therapeutic techniques presented. It is thus possible that the results could differ from a similar study made in a face-to-face context. A replication in such a setting is recommended. Due to the above limitations, the results should be interpreted with caution and viewed in the context of other studies on the topic of comorbid insomnia and depression. Taken together, the evidence to date points to the treatment of insomnia as being important for this patient group, both as a way of reducing insomnia severity long term, as a mediator in the recovery from depression, and possibly as prevention of relapse into depression. This calls for an increased and more specific focus on treating insomnia when it is presented together with depression.
CONCLUSION
CBT-i was effective in treating both insomnia and depression, and the results were maintained 3 years after treatment. According to this and other studies on this patient group, patients with co-occurring insomnia and depression should ideally be offered CBT-i in addition to medication or psychological treatment for depression. 
